RURAL SCREENING CENTRE FOR PELVIC INFLAMMATORY DISEASE AND ITS EFFECTIVE MANAGEMENT WITH AYURVEDIC FORMULATIONS

Phase 3

Conditions: Health Condition 1: null- Diagnostic cases of PID

Registration Number: CTRI/2017/09/009820

Lead Sponsor: Vision Group on Science and Technology

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Married women in their 20-50yrs age group

2.Patients presenting with symptoms of vaginitis, cervicitis, endometritis and oophoritis

3.Patients presenting with mucopurulent per vaginal discharges

4.Diagnosed cases of chronic P.I.D.

5.Patients presenting with irregular menstruation and spotting due to P.I.D Patients presenting with deep seated dyspareunia ,post coital pain or discomfort due to P.I.D

6.Patients with tubo-ovarian mass of inflammatory origin

7.Cervical erosion, nebothian cysts, CIN Grade I & II

8.Borderline hypertensive patients are included

Exclusion Criteria

1.Patients with CIN Grade III, STDs, Malignancy

2.Patients with Copper T in situ

3.Women with Pregnancy

4.P.I.D complicated with DM/moderate to severe HTN/ TB

5.Patients with acute P.I.D and peritonitis

6.P.I.D associated with prolapsed uterus

7.Patients with endometriosis/chocolate cyst/cervical polyp/

8.Patients with exclusively vulvitis and bartholinitis

9.P.I.D associated with senility and menopause.

10.Patients who require surgical interventions in cases like pelvic abscess

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. study the impact of the Ayurvedic combination on the vaginal pathological microbial load and swab culture. <br/ ><br>2. see the efficacy of the drug in restoring the fertility of the eligible couples after the subsidence of the disease. <br/ ><br>3. screen the female patients of reproductive age group at SDM Hospital of Ayurveda for the detection of pelvic inflammatory disease (PID). <br/ ><br>study the efficacy of the selected drug combination in the management of PID.Timepoint: 45 days

Secondary Outcome Measures